Gerth Hans-Ulrich, Pohlen Michele, Thoennissen Nils-Heinrich, Suwelack Barbara, Pavenstädt Hermann-Josef, Störkel Stefan, Abbas Mahmoud, Spieker Tilmann, Thölking Gerold
Department of Medicine D, Division of General Internal Medicine, Nephrology and Rheumatology, University Hospital of Münster, D-48149 Münster.
Oncol Lett. 2012 Jul;4(1):80-82. doi: 10.3892/ol.2012.704. Epub 2012 May 4.
Papillary renal cell carcinoma (PRCC) is a rare malignant tumor entity compared to common clear cell renal carcinoma. In the present study, we report a patient who was diagnosed with PRCC twice and successfully treated each time following renal transplantation. The first PRCC was located in the left native kidney two years following transplantation, and the second PRCC was diagnosed in the allograft 13 years following transplantation. The two tumors were completely removed by surgery in stage I of the disease with sufficient conservation of the allograft function. Notably, the tumors had a different origin as indicated by the microsatellite analysis, which reflects the exceptional course of the case. Risk factors for PRCC were identified in our patient. We concluded that high-risk candidates for malignancies in renal transplant recipients should receive shorter ultrasonic screening intervals, which may facilitate early tumor detection and improve outcome rates.
与常见的透明细胞肾细胞癌相比，乳头状肾细胞癌（PRCC）是一种罕见的恶性肿瘤。在本研究中，我们报告了一名患者，该患者两次被诊断为PRCC，每次肾移植后均成功接受治疗。第一次PRCC位于移植后两年的左肾原肾中，第二次PRCC在移植后13年的同种异体移植中被诊断出。在疾病的I期通过手术将两个肿瘤完全切除，同时充分保留了同种异体移植功能。值得注意的是，微卫星分析表明这两个肿瘤起源不同，这反映了该病例的特殊病程。我们的患者中确定了PRCC的危险因素。我们得出结论，肾移植受者中恶性肿瘤的高危候选人应接受更短的超声筛查间隔，这可能有助于早期肿瘤检测并提高治愈率。
